1500 Broadway
Suite 1401
New York, NY 10036
United States
332 208 6102
https://www.nuvationbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 51
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. David T. Hung M.D. | Founder, President, CEO & Director | 1M | N/A | 1958 |
Ms. Stacy Markel | Chief People Officer | N/A | N/A | 1965 |
Dr. Junyuan Wang Ph.D. | CEO & Co-Founder of AnHeart Therapeutics and Director | N/A | N/A | 1973 |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 10; Compensation: 10.